Making hay while the sun shines on cellular therapies, Seattle-based Juno Therapeutics Inc. is raising up to $318.7 million in a public follow-on offering and concurrent private placement with its partner Celgene Corp. Juno shares (NASDAQ:JUNO) rose 8.5 percent on the news, to close at $45.14 on Friday.